Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17448117 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL23556116 | 0.87 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL21070491 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL21069484 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL21111181 | 0.81 | SLC6A2 (0.34) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL10512462 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL1633115 | 0.80 | SSTR4 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL3102536 | 0.80 | SSTR4 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL2767957 | 0.80 | SSTR4 (0.35) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A | |
| SCHEMBL21069498 | 0.79 | SLC6A4 (0.34) | SLC6A2SLC6A3SLC6A4ADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | SLC6A2 4274/4885SLC6A3 4126/4885SLC6A4 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.